Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

NCT06071013 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer
EGFR Gene Mutation
EGFR-TKI Resistant Mutation

Interventions

DRUG: Nintedanib, gefitinib, erlotinib, afatinib, osimertinib

Sponsor

China Medical University Hospital

Collaborators

[object Object]